No Data
No Data
Google To Introduce Choice Experience In Chrome Instead Of Deprecating Third-Party Cookies; Will Continue Developing Privacy Sandbox APIs For Enhanced Privacy And Utility; Plans To Add IP Protection To Incognito Mode
Google To Introduce Choice Experience In Chrome Instead Of Deprecating Third-Party Cookies; Will Continue Developing Privacy Sandbox APIs For Enhanced Privacy And Utility; Plans To Add IP Protection
CMA Accepts Google's Commitments On Third-Party Cookies
CMA Accepts Google's Commitments On Third-Party
Meta Platforms Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 17.68% Bernstein $565 → $575 Maintains Outperform 07/19/2024 7.45% Oppenheimer $500 → $525
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering immunology therapeutics.AnaptysBio has a pipeline of checkpoint
S&P 500, Nasdaq Rebound, as Nvidia, Tesla and Rest of Magnificent Seven Rally
The
Citi Sees S&P Companies Beating Q2 EPS Estimates on Productivity Gains in the Labor Market